

mgc pharma



Leading The Way in Phytocannabinoid Derived Medicines
with a Seed-to-Pharmacy Strategy

Company Presentation
October 2019



Disclaimer

This presentation has been prepared by MGC Pharmaceuticals Limited (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US disclosure

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

Investment Highlights

MGC Pharma is an industry leading, European bio-pharma company supplying GMP Phytocannabinoid derived medicines to patients globally

- ✓ Authorised products targeting medical conditions: epilepsy and dementia
- ✓ Additional targeted products in development pipeline
- ✓ Growing patient base in Australia and the UK, access to new key EU and Asian markets in process
- ✓ EU-GMP certified manufacturing facility, one of few globally to manufacture phytocannabinoid derived medicines
- ✓ Global distribution footprint via extensive network of commercial partners
- ✓ Highly qualified management team, supported by leading scientific experts
- ✓ Construction has commenced in Malta for a multi-story building 10,480m² combined manufacturing facility including GMP certified processing and production, with a 5,240m² greenhouse on the roof for cultivation

Global Footprint

For personal use only

United Kingdom:

- European Corporate Headquarters
- Planned LSE Standard dual listing 2019

Slovenia: Primary Research Base

- Botanical and Pharma research base
- Manufacturing centre with EU GMP certification

Malta: Primary Operation Base

- Main EU production facility
- Research & Development
- Cultivation facility

Israel: Science and Research Team

Australia: R&D HUB & Corporate HQ

- Corporate and Financial office
- ASX Listed since 2016
- R&D HUB with RMIT

In Numbers

Established EU-GMP licence approved leader in the cannabis space

2

Operations
Facilities

Malta & Slovenia

Over 15

Years Experience in

Medical Cannabis Research

R&D team backed by extensive
industry experience

3

Developed
Products

And pipeline of potential
products in development

Network of
over 30
International
Partners

Cannabis for
Medicinal use
value to reach
£46bn*
(AU\$82.8bn) in
2026

200

Prescriptions Issued
in 3 months in 2
jurisdictions

Global Market

For personal use only

OVERVIEW

MARKET

APPENDIX



Estimated cannabis for medicinal use value
£47billion
in 2028




Cannabis based medicine sales to increase by
182%
2016-2020



Europe to be largest medical cannabis market.
Total healthcare spend:
£2.1t



Nov 1st 2018
UK legalised prescription of medical cannabis products



- MGC Pharma aims to secure a significant share in the global Cannabis Pharmaceutical Market
- MGC Pharma targets large markets, where cannabis for medical use is likely to have a high degree of success
- 3 pharmaceutical products in late stage development

Board of Directors

Highly qualified team with over 15 years of relevant experience



Roby Zomer
Managing Director, CEO & Founder

Brett Mitchell
Executive Chairman

Nativ Segev
Director, Head of Business Strategy & Founder

Dr. Stephen Parker
Director & Chairman of Audit, Risk, Nomination and Remuneration Committees

Dr. Ross Walker
Director & Head of Medical Advisory Board

Following 10 years of experience in the BioTech and AgroTech sectors alongside running large scale projects, Mr. Zomer joined MGC Pharmaceuticals as Executive Director & CTO, bringing his extensive business contacts, scientific and engineering skillset to bear on ensuring MGC's position as a leader in research and development, as well as ensuring top performance from our global operations.

With over 20 years of experience in the founding, financing and management of both private and publicly listed companies, Mr. Mitchell is responsible for the corporate strategy, capital markets and financial management of the company, and is integrally involved in assisting in building a new industry from the ground up in Australia.

The founder of MGC Pharma, previously CEO of a Israeli licensed Medical Cannabis company, with over 10 years of experience in the global medical cannabis industry and over 15 years of experience in executive roles. Founded MGC Pharma to expand into the International markets and to raise the quality and viability of medicinal phytocannabinoid products.

Dr. Parker has over 30 years of corporate finance, directorship, corporate advisory and investment banking experience focused on the pharmaceutical and biotechnology sectors in the UK, Europe and North America. Dr. Parker is regarded as a leading corporate expert and strategic thinker. He has a reputation for rapid and clear analysis and the ability to translate this analysis into an implemented solution.

Dr. Walker is a well-known figure in Australian health, as former host of a weekly radio programme and a prominent cardiologist who specialises in echocardiography and preventative cardiology. Dr. Walker has published several books, and lectures both nationally and internationally. His contacts in the medical establishment and beyond allow him to facilitate relationships for MGC and draw positive public attention to the brand.

Scientific Team

Leading experts in the medical cannabis space with unparalleled expertise

For personal use only

				
Dr. Jonny Grunfeld	Professor Uri Kramer Head of Neurology product development	Professor David Neubauer	Professor Stane Srčič	Professor Nadya Lisovoder
Certified in Israel, with clinical experience at the MD Andersen Cancer Center, [Prof]. Grunfeld has spent the last twenty years focusing on Neuro-Oncology, with a focus since 2010 on Cannabis as a treatment for oncological palliative care. Involved in the licensing of care of over 3000 medical cannabis patients in Israel, giving him a unique insight into questions of dosing, patient groups and developing treatment methodology.	One of the few medical professionals in the world to have run full scale epilepsy trials with Cannabis, Dr. Kramer brings a wealth of experience in various fields (Neurology, Pediatric Neurology, Adolescent Psychology & Child Development). Additionally, Professor Kramer is a Former president of the Israeli League Against Epilepsy, giving him unique insight into the daily struggles of the patients his research benefits.	As Head of Department of Child, Adolescent and Developmental Neurology at University Children's Hospital, Ljubljana, Dr Neubauer is widely published and respected, and has dealt with children and adolescents in Neurological contexts for more than thirty years.	Stane Srčič is a Professor of Pharmaceutics and Head of the Department of Pharmaceutics at the University of Ljubljana, where he held the position of Vice-Dean between 1996 and 2000. From 1987-88 he was Assistant and Associate Professor in Ljubljana before becoming a full Professor and taking on the role of Head of Department.	15 years of domestic and international experience in academic and clinical studies in the pharmaceutical, diagnostic and medical devices industry. Dr. Lisovoder is a regulatory expert and has been a clinical adviser to public biotech companies as well as incubator companies. She has managed clinical trials and has been leading for the Israeli government biomedical research in 7 hospitals in northern Israel in cooperation with universities, international Pharma companies, global CROs and biotech companies.

Vision

Building an industry leading global bio-pharma company,

With: Cost effective, Compliant, Affordable medicine


2. Advance commercialisation strategy into targeted global geographies



1. Engage in continuous research to maintain cutting edge position– Botanical and Pharmaceutical for the highest regulatory compliance medicines (EMA)



3. Strengthen partnerships to promote new pipeline of new products to be affordable globally



4. Control entire production chain to provide cost-effective medicine



5. Become cash flow positive following ramp up of revenue post EU clinical trials

Company Snapshot

MGC Pharma is at the forefront of Global Phytocannabinoid derived medicines

FIRST PRODUCT TO MARKET

- CannEpil® is a phytocannabinoid product aimed for **drug-resistant epilepsy**
- Being provided to patients in Australia and UK via the **early access schemes** ahead of registration
- Price point and **efficacy** will make it a strong alternative to current medicines

RESEARCH EXCELLENCE

- Landmark collaboration agreement signed between MGC, RMIT and the Hebrew University to establish **CannaHub**
- Establishing the **International Library of Cannabinoids** focusing on research on melanoma and prostate cancer
- Developing the **CannEpil® App**



BEST-IN-CLASS MANUFACTURING

- **EU-GMP certification** granted for production of phytocannabinoid based Investigational Medicinal Products (Europe)
- MGC Facilities are **unique** in Europe, allowing the development of medicines and API
- **SME approval** by the **European Medicines Agency** (EMA) for scientific advice and incentives

EDUCATION AND PATIENT ACCESS

- Strategic Alliance with Australia's leading epilepsy association, **Epilepsy Action Australia**
- MGC products will be introduced by EAA to members
- Collaboration on developing **C4E campaign** to increase awareness and access to medication



Seed to Pharmacy Manufacturing

Creation and commercialisation of Phytocannabinoid derived products through a vertically integrated model utilising in house R&D capability

Global Operation

- Multi-National base
- EU-GMP certified facility, from API to compounded product
- Pharma European R&D HQ in Slovenia
- Cultivation R&D in Slovenia

New Centralised EU Hub

- Maltese Facility to become primary operations hub
- Fully integrated supply chain with easy access to European markets
- To involve a 10,480m² combined manufacturing facility including GMP certified processing and production, with a 5,240m² greenhouse on the roof for cultivation



CULTIVATION

High THC >35% strains
High CBD >20% Strains



EXTRACTION &
ISOLATION INTO API

Super Critical (Co²)
Alcohol Extraction



CLINICAL TRIALS

Europe (EMA)
Australia (TGA)



PRODUCT
DEVELOPMENT

Europe
Australia
Israel




DISTRIBUTION

Europe
Australia
South America

MGC Research & Development

3 research arms based on medical experience and large data collections



Products – Pharmaceuticals

Targeting specific medical conditions such as epilepsy and dementia

CANN_EPIL[®]

Epilepsy

- Oral oil solution to treat seizures associated with drug resistant epilepsy
- Based on long term observation research published in Israel by Prof. Uri Kramer
- Phase IIb submitted in Slovenia for EMA
- Early access schemes in Australia and UK

COGNI_CANN


Dementia

- Oral spray utilising a specific THC:CBD ratio for relief of dementia symptoms
- Based on longitudinal research in Israel
- Phase IIb submitted in Australia, patient recruitment started
- Early access schemes in Australia and UK

IN_CANN

IBS

- Bioactive Capsule for symptoms of Crohn's disease and Irritable Bowel Syndrome (IBS)
- Based on observational research in Israel and pre-clinical on humans in Europe



FURTHER PRODUCT PIPELINE

Pipeline of phytocannabinoid derived medications, APIs and unique formulations all manufactured under GMP certified facilities to be used in pharmaceutical treatment and research

CannEpil[®]

CannEpil[®] is a Phytocannabinoid derived IMP used as a treatment for refractory epilepsy

CANN_EPIL[®]

- Authorized to prescribe in Australia and UK through early patient access schemes
- Over 500,000 epilepsy patients in UK
- Over 250,000 epilepsy patients in Australia
- At least 6,000,000 people have epilepsy in Europe
- Approximately 30% of people with epilepsy have a drug-resistant form
- Expected time to marketing authorization 4 years

CannEpil[®] is an oral oil solution of cannabidiol (CBD) and (-)- trans- Δ^9 -tetrahydrocannabinol (THC).

Produced from two proprietary, preselected, specifically bred genotypes of the cannabis plant with a stable and specific ratio of cannabinoids.

MGC's first pharmaceutical-grade medical product targeted for drug resistant (refractory) epilepsy, which accounts for approximately 30% of the people diagnosed with epilepsy.

Neurological Disorders

Epilepsy

The epilepsy medication market is approximately £3bn

CogniCann™

CogniCann™ is MGC second Phytocannabinoid derived IMP designed to improve dementia and Alzheimer's patients quality of life

COGNICANN™

- Authorized to prescribe in Australia and UK through Early Patient Access Scheme
- Over 800,000 dementia patients in UK
- Over 400,000 dementia patients in Australia
- At least 10,000,000 people with dementia in Europe
- Expected time to marketing authorization 4 years

CogniCann™ is a sublingual spray of cannabidiol (CBD) and (-)- trans-Δ9-tetrahydrocannabinol (THC).

Produced from two proprietary, preselected, specifically bred genotypes of the cannabis plant with a stable and specific ratio of cannabinoids.

1mL of CogniCann™ contains 25mg THC and 17mg CBD. Beside THC and CBD, CogniCann™ contains a minor amount of additional specific cannabinoids and terpenes from cannabis plant that are working synergistically with CBD and THC to maximize the efficiency.

Neurological Disorders

Dementia

The dementia medication market is approximately £11.3bn

Research and Development

- Developing medicines that leverage its proprietary medical cannabis formula through successful clinical trials in Europe, Australia
- This will enable future medical product sales across the EU, Australia and other geographies, following the requisite legal and regulatory approvals

Neurological

CepaCann Oral Spray to treat Cerebral Palsy

Preclinical in process

ONCOLOGICAL & CANCER SIDE EFFECTS

Tetrinol Treatment of Anorexia Cachexia in Cancer Patients

MXOT02GB01 Treatment of Glioblastoma (NIB)

MXOT02ME01 Treatment of Melanoma Cancer (RMIT/CannaHub)

MXOT02PC01 Treatment of Prostate Cancer (RMIT/CannaHub)

Preclinical in process

AUTOIMMUNE DISEASE – INFLAMMATORY

TopiCann Topical treatment of Eczema and inflamed skin (RMIT/CannaHub)

Study Results: 70% Reduction in 4 weeks

MXAI01AB01 Antibacterial topical cream (RMIT/CannaHub)

Preclinical in process

Q2 2016
R&D Division
Established

- Establishing research programme
- Building the Scientific Advisory Board

Q1 2017
Pre-Clinical
Programme Initiated

- Collecting clinical data
- Design protocols for first product to market

Q3 2018
EU GMP
Approved

- First of its kind in the EU – authorised for production

Q4 2018
Authorised
Prescribers Approved

- First IMP CannEpiI authorised for prescription by the TGA in Australia

Q1 2019
EMA SME
Qualification


- Allows advice, drug evaluation and registration with a 100% reduction in fees



Strategic Partnership with RMIT



MGC Pharma and RMIT developing CannaHub, a digital research hub for the application of Phytocannabinoid derived medicines including the International Library of Cannabinoids (ILC)



CannaHub provides an interface connecting doctors and patients with clinical research and information on cannabinoid sequences and their potential treatments

INTERNATIONAL LIBRARY OF CANNABINOIDS

- ILC is the World's first library of cannabis medicine where details of medical cannabis clinical research, cannabinoid sequences and their treatments can be found
- ILC will collect data from diverse clinical studies, academic publications, patient feedback as well as diverse cannabinoid strains
- Collected and analysed data from the ILC will assist and enhance the work of doctors and researchers and improve industry efficacy estimates of cannabinoid treatment of various disorders
- ILC could be utilised for the design and implementation of clinical trials via its mobile and web-based applications


Cannabinoids and Brain Cancers

Pre-clinical research conducted in collaboration with the National Institute of Biology and University Medical Centre Ljubljana

Research highlighted the positive impact of using specific cannabinoid formulations in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour and, as such can be considered a major scientific breakthrough in the application of cannabinoid compounds on cancerous cells.

Key Highlights:

- Recent report on pre-clinical research focuses on the development of cannabinoid formulations specifically tailored for the effective treatment of high grade brain tumours
- Represents first research to test the effects of cannabinoid compound formulations on cancerous cells using tissues taken directly from a patient
- This report confirms that cannabinoid preparations can successfully inhibit tumour viability and also cause the significant fraction of glioblastoma cells to die i.e. apoptosis after short time after their application
- Most importantly, cannabinoid formulations are shown to be able to target glioblastoma stem cells that are considered to be the “roots” of the disease and the critical target in oncology therapy
- These multi compound cannabinoid formulations are the intellectual property of MGC Pharmaceuticals
- A diagnostic platform for glioblastoma patients has been developed that is able to predict the response of a tumour to selective multi-cannabinoid compound formulations, meaning that a targeted treatment plan can be most efficiently implemented



Cultivation & Production

CULTIVATION

- Active engagement with multiple cultivation sites to meet increasing global demand
- Specialised controlled cultivation also underway for research into breeding and genetics, in partnership with leading institutions and academia
- Raw material used for extraction and isolation into Active Pharmaceutical Ingredients (API)

OBJECTIVE: To refine and regulate MGC's genetic bank to guarantee the ability to produce flawless, high quality products globally

Key Partnerships:

- University of Ljubljana – Bio faculty – research into the development of new genetic strains
- IHPS (HOP institute Slovenia) – research into the improvement of technical growing parameters
- Safe Pharma Macedonia – commercial cultivation partner

Jurisdictions:

- 2017-19 Czech Republic
- Slovenia and, Malta from 2021

PRODUCTION

- Production of high quality pharmaceutical products to be used as part of a prescribed medical treatment plan
- Pharmaceutical products initially targeting treatment of epilepsy, IQL in dementia and Alzheimer's, Oncological care and Autoimmune diseases
- Also includes compounding of phytocannabinoid based API

OBJECTIVE: The production of high quality, consistent, cost effective medicines targeting common illnesses and diseases

Key Partnerships:

- University of Ljubljana – Clinical Centre – Research in Epilepsy
- National Institute of Biology (NIB) – Research in Brain Cancer
- Royal Melbourne Institute of Technology (RMIT) - Research in Brain Cancer and Autoimmune diseases

Jurisdictions:

- Slovenia, Australia and upcoming, Malta

Commercial Production: Malta – a Centralised Hub

Establishing a fully vertically integrated medical cannabis “Seed to Pharmacy” operation in the EU

Signed long-term lease on 6,000m² site for full medical cannabis facility providing direct access to the EU

One of the first cannabis industry companies to sign a long-term lease agreement with the Maltese government to develop a fully integrated GMP compliant medical cannabis production facility in Malta. Facility will include cultivation, production and research of MGC Pharma cannabinoid derived medicines for global distribution.

First federal bill on legalising medicinal cannabis in Malta passed in parliament during March 2018.



Medical Cannabis legalised in Malta – provides direct access to the EU

Malta is highly strategic for the success of the Company's EU focused business and operations plan.


Climate is ideal for cannabis cultivation and allows three crop cycles per year.

As part of the EU, Malta is favourable for the construction of large scale operations.

- MGC will establish turnkey “Seed to Pharmacy” state-of-the-art EU GMP production facility to provide its medicines globally
- Large scale, eco friendly commercial facility will be a 15,720m² multi-story facility with production capacity of over 8,000 units per hour of each product
- Access to existing operational and distribution pipelines in Europe and Australia
- Direct access to key emerging markets through the FDA Mutual Recognition agreement signed with Austria, Croatia, France, Italy, Malta, Spain, Sweden and the UK


Malta facility – Architectural Design of Malta Hub

Front view



E03 PROPOSED ELEVATION 1
SCALE 1:100

Side view



E03 PROPOSED ELEVATION 3
SCALE 1:100

Key Wholesaler Partner

LENIS – A FULL-SERVICE PHARMACEUTICAL DISTRIBUTOR

Lenis specializes in the distribution of unlicensed drugs and niche therapeutic areas (licensed in the source country but not in the destination country). This includes:

- New drugs not yet approved in a country
- Discontinued cost-effective drugs (e.g. infertility, ophthalmology, infectious diseases)
- Product alternatives during drug shortages (e.g. oncology)
- Comparator drugs for clinical trials

Lenis provides added value products in niche therapeutic areas and the distribution of innovative pharmaceutical products and generic pharmaceuticals with limited number of competitors.

Its core principal is Gilead Sciences, Inc.

Lenis partnership provides the Company with:


- Knowledge on regulatory affairs
- Market access
- Medical Support
- Marketing & Sales
- Wholesale & Distribution
- Pharmacovigilance



Key Distribution Partners

Extensive network in place providing access to hospitals, pharmacies and research institutions around the world

AUSTRALIA



Health House specialist as wholesales and distributes of medical cannabis to and in Australia




Cannvalate has a network of over 1,000 doctors and 600 pharmacies across Australia

SOUTH AMERICA



Distributor with has a disruptive digital strategy to capture leads of potential patients and connect them with the physicians they need

EUROPE




Distribution channels with a strong distribution network of over 5,500 pharmacies that can fulfil prescriptions direct to a patient's door



Mexacare provides the sales, marketing and logistics for diagnostic devices and complementary medical products to pharmacies, labs, hospitals and doctors




AFRICA



Founded in 1978, AM MANGION has grown into a top-ranking healthcare company Distributor of Gilead Sciences, Inc and J&J


ASIA



Strategic Milestones

Achieving values over time as “Seed to Pharmacy” Bio-Pharma Company

For personal use only



Investment Case

Fully Integrated Model: Grow → Develop → Commercialise

Built on Decades of Experience

Technical team of globally recognised scientists and doctors

Focussed Operations

Core divisions:

Research and Development

Manufacturing and Distribution

Strategically Located

Operational bases close to key markets supported by corporate headquarters

Robust Product Offering

Portfolio of established and upcoming products targeting key markets

International Reach

Network of research and commercial partners globally

Strong Market Outlook

Global phytocannabinoid market gaining traction



For personal use only

mgc pharma 

 <https://mgcpharma.com.au/>

 @mgcpharmaceuticals

 @MGC_Pharma

 MGC Pharmaceuticals, Ltd.

Financial PR:

 St Brides Partners
(+44) 02072361177

info@stbridespartners.co.uk